Our leukemia and lymphoma research
Photo courtesy of NCI Visuals Online
Lymphoma is a broad term for cancer that begins in cells of the lymph system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma can often be cured, but the prognosis of NHL depends on the specific type. Leukemia is a broad term for cancers of the blood cells. The type of leukemia depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. Leukemia occurs most often in adults older than 55, but it is also the most common cancer in children younger than 15.
Our Lymphoid Malignancies Branch focuses on the identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. The branch received funding from the Cancer Moonshot Blue Ribbon Panel to conduct a precision medicine clinical trial of relapsed/refractory diffuse large B-cell lymphoma and identify mechanisms of resistance.
We have a number of researchers who are advancing research discoveries and treatments in this area of hematologic cancers.
Louis Staudt, M.D., Ph.D., and Elaine Jaffe, M.D., have been redefining lymphoma by determining the molecular subtypes of the disease allowing for more precise treatment options for patients. Dr. Staudt has discovered an essential gene network that suggests a potential therapy for adult T-cell leukemia/lymphoma and a protein complex that could be key to drug responsiveness in lymphoma patients.
Wyndham Wilson, M.D., Ph.D., is using combinations of targeted agents to treat lymphoma patients.
Mark Roschewski, M.D., is leading a number of lymphoma-related clinical trials, including a trial that uses a targeted cancer drug to treat lymphatic system disease and a trial that uses combination therapy for certain types of non-Hodgkin lymphoma.
Explore our website further to learn about other CCR researchers who are conducting leukemia and lymphoma research.Tue, 09/01/2020